San Diego, CA—Tobacco researchers and regulators lauded progress in tobacco control, but they emphasized that the health burden of tobacco use continues, reflecting the expanding list of diseases caused or exacerbated by tobacco.
Chicago, IL—According to a survey presented at the 2014 American Society of Clinical Oncology (ASCO) meeting, the majority of patients with cancer want to have cost-of-treatment discussions with their oncologists. And when they occur, these discussions do not lead to negative feelings in most patients.
Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Chicago, IL—The US Food and Drug Administration (FDA) introduced the concept of a breakthrough therapy designation in 2012 to help expedite patient access to new therapies for the treatment of serious or life-threatening diseases.
Chicago, IL—The US Preventive Services Task Force (USPSTF) recommends annual low-dose computed tomography (LDCT) lung cancer screening for patients at high risk. What would it mean in terms of cost to society if those recommendations were implemented in the Medicare population?
Chicago, IL—Obesity increased the risk for breast cancer–associated death in premenopausal patients with estrogen receptor (ER)-positive breast cancer, had little effect in postmenopausal women with ER-positive disease, and had no effect in patients with ER-negative disease, according to results of a large study of 80,000 women with early breast cancer that were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Chicago, IL—AZD9291, a novel mutation-selective tyrosine kinase inhibitor (TKI), may become a treatment option for patients with advanced, EGFR-mutated non–small-cell lung cancer (NSCLC) that has progressed with standard EGFR inhibitors, according to results of a phase 1 study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Chicago, IL—A head-to-head comparison of 2 monoclonal antibodies for metastatic colorectal cancer (mCRC) has shown no difference in their benefit when paired with chemotherapy in the first-line setting.
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. The American Society of Clinical Oncology (ASCO) released new clinical practice guidelines for the treatment of women with advanced HER2-positive breast cancer, focusing on systemic therapies.
Orlando, FL—Delaying a prostate-specific antigen (PSA)-triggered prostate biopsy to allow for additional PSA assessments might have avoided more than 70% of subsequent biopsies, according to a study of negative biopsies for >28,000 men reported at the 2014 American Urological Association annual meeting.
Page 1 of 4
Results 1 - 10 of 32
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology